BR9307387A - Agentes terapêuticos - Google Patents
Agentes terapêuticosInfo
- Publication number
- BR9307387A BR9307387A BR9307387-9A BR9307387A BR9307387A BR 9307387 A BR9307387 A BR 9307387A BR 9307387 A BR9307387 A BR 9307387A BR 9307387 A BR9307387 A BR 9307387A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- optionally substituted
- halo
- phenyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
<MU>AGENTES TERAPêUTICOS<MV> Compostos de fórmula I onde n = 0, 1 ou 2; R~ 1~, R~ 2~, R~ 6~ e R~ 7~ independentemente representam H ou alquila (opcionalmente substituído por um ou mais halo); R~ 3~ e R~ 4~ independentemente representam H ou alquila ou juntos representam um grupo de fórmula =NR~ 12~ onde R~ 12~ representa H, hidroxi, alquila, fenila ou alcoxi; cada alquila, fenila e alcoxi estando opcionalmente substituído com um ou mais halo; R~ 5~ representa: (a) H, (b) alquila, (c) um grupo de fórmula -COR~ 13~ no qual R~ 13~ é H, alquila ou fenila, quando R~ 3~ e R~ 4~ representam H ou alquila (opcionalmente substituído com um ou mais halo), ou (d) um grupo de fórmula -S(O) pR~ 14~ no qual p = 1 ou 2 e R~ 14~ é alquila ou fenila, quando R~ 3~ e R~ 4~ representam H ou alquila (opcionalmente substituído com um ou mais halo); cada alquila e fenila opcionalmente substituído com um ou mais halo; e R~ 8~ a R~ 11~ independentemente representam H, halo, ciano, nitro, alquila, alcoxi, alcanoíla, carboxi, alcanoiloxi, carbamoíla (opcionalmente substituído com alquila ou sulfamoíla (opcionalmente substituído com alquila de 1 a 4 átomos de carbono); cada alquila, alcoxi, alcanoíla ou alcanoiloxi opcionalmente substituído com um ou mais halo; têm utilidade no tratamento de ataques e/ou desordens neurológicas tais como epilepsia e/ou como agentes neuroprotetores para proteção contra condições tais como acesso.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929223441A GB9223441D0 (en) | 1992-11-09 | 1992-11-09 | Therapeutic agents |
| GB929223443A GB9223443D0 (en) | 1992-11-09 | 1992-11-09 | Therapeutic agents |
| PCT/EP1993/003123 WO1994011360A1 (en) | 1992-11-09 | 1993-11-06 | 1,4-benzothiazepines useful as neurological agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9307387A true BR9307387A (pt) | 1999-08-31 |
Family
ID=26301938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9307387-9A BR9307387A (pt) | 1992-11-09 | 1993-11-06 | Agentes terapêuticos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5580866A (pt) |
| EP (1) | EP0667866B1 (pt) |
| JP (1) | JPH08503202A (pt) |
| KR (1) | KR100313649B1 (pt) |
| AT (1) | ATE163927T1 (pt) |
| BG (1) | BG62519B1 (pt) |
| BR (1) | BR9307387A (pt) |
| CA (1) | CA2148584A1 (pt) |
| CZ (1) | CZ288595B6 (pt) |
| DE (1) | DE69317436T2 (pt) |
| DK (1) | DK0667866T3 (pt) |
| ES (1) | ES2113081T3 (pt) |
| FI (1) | FI952204A (pt) |
| GR (1) | GR3026386T3 (pt) |
| HU (1) | HUT71819A (pt) |
| NO (1) | NO304467B1 (pt) |
| NZ (1) | NZ257843A (pt) |
| PL (1) | PL179401B1 (pt) |
| RU (1) | RU2115650C1 (pt) |
| SK (1) | SK280522B6 (pt) |
| UA (1) | UA41342C2 (pt) |
| WO (1) | WO1994011360A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693636A (en) * | 1991-06-28 | 1997-12-02 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| US5939412A (en) * | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| MA23420A1 (fr) * | 1994-01-07 | 1995-10-01 | Smithkline Beecham Corp | Antagonistes bicycliques de fibrinogene. |
| US6458784B1 (en) | 1994-06-29 | 2002-10-01 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| GB9506382D0 (en) * | 1995-03-29 | 1995-05-17 | Boots Co Plc | Pharmaceutical compositions |
| US5977101A (en) * | 1995-06-29 | 1999-11-02 | Smithkline Beecham Corporation | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity |
| ZA9610853B (en) | 1995-12-29 | 1998-04-06 | Smithkline Beecham Corp | Processes and intermediates for preparing pharmaceuticals. |
| GB9616279D0 (en) * | 1996-08-02 | 1996-09-11 | Knoll Ag | Chemical process |
| PT864582E (pt) * | 1997-03-14 | 2003-10-31 | Aventis Pharma Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos |
| GB9914745D0 (en) * | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7393652B2 (en) | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
| US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| AU2004220548A1 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
| US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| WO2009111463A1 (en) * | 2008-03-03 | 2009-09-11 | Armgo Pharma, Inc. | Process for preparing benzothiazepines from gamma-aminoalkylbenzenes |
| WO2013064231A1 (en) | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
| EP2708535A1 (en) | 2012-05-11 | 2014-03-19 | Les Laboratoires Servier | Agents for treating disorders involving modulation of ryanodine receptors |
| KR102157141B1 (ko) | 2018-11-27 | 2020-09-17 | 주식회사 파미니티 | 으아리 추출물을 유효 성분으로 포함하는 인지 기능 개선용 조성물 |
| KR102172916B1 (ko) | 2018-12-07 | 2020-11-02 | 주식회사 파미니티 | 실크 펩타이드 및 천연 추출물을 포함하는 인지 기능 개선용 조성물 |
| JP2023549583A (ja) * | 2020-11-17 | 2023-11-27 | アームゴ・ファーマ・インコーポレーテッド | リアノジン受容体関連障害治療用薬剤 |
| US11504383B2 (en) | 2021-01-08 | 2022-11-22 | Armgo Pharma, Inc. | Crystalline forms of a Ryanodine receptor modulator and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3362962A (en) * | 1964-01-24 | 1968-01-09 | Hoffmann La Roche | Certain benzothiazepine derivatives |
| US3682962A (en) * | 1970-03-17 | 1972-08-08 | Sterling Drug Inc | 1-substituted-1,2,3,5-tetrahydro-4,1-benzothiozepines |
| EP0368063B1 (de) * | 1988-11-05 | 1992-06-10 | Bayer Ag | Verfahren zur Kernchlorierung von aromatischen Kohlenwasserstoffen |
| JP2703408B2 (ja) * | 1990-12-28 | 1998-01-26 | 麒麟麦酒株式会社 | １，４‐ベンゾチアゼピン誘導体 |
| GB9111376D0 (en) * | 1991-05-25 | 1991-07-17 | Boots Co Plc | Therapeutic agents |
| GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
-
1993
- 1993-11-06 CZ CZ19951176A patent/CZ288595B6/cs not_active IP Right Cessation
- 1993-11-06 BR BR9307387-9A patent/BR9307387A/pt not_active Application Discontinuation
- 1993-11-06 DE DE69317436T patent/DE69317436T2/de not_active Expired - Fee Related
- 1993-11-06 PL PL93308757A patent/PL179401B1/pl unknown
- 1993-11-06 US US08/424,464 patent/US5580866A/en not_active Expired - Fee Related
- 1993-11-06 CA CA002148584A patent/CA2148584A1/en not_active Abandoned
- 1993-11-06 HU HU9501352A patent/HUT71819A/hu unknown
- 1993-11-06 UA UA95062705A patent/UA41342C2/uk unknown
- 1993-11-06 JP JP6511695A patent/JPH08503202A/ja not_active Withdrawn
- 1993-11-06 NZ NZ257843A patent/NZ257843A/en unknown
- 1993-11-06 SK SK588-95A patent/SK280522B6/sk unknown
- 1993-11-06 DK DK94900113.5T patent/DK0667866T3/da active
- 1993-11-06 WO PCT/EP1993/003123 patent/WO1994011360A1/en active IP Right Grant
- 1993-11-06 EP EP94900113A patent/EP0667866B1/en not_active Expired - Lifetime
- 1993-11-06 AT AT94900113T patent/ATE163927T1/de not_active IP Right Cessation
- 1993-11-06 ES ES94900113T patent/ES2113081T3/es not_active Expired - Lifetime
- 1993-11-06 KR KR1019950701831A patent/KR100313649B1/ko not_active IP Right Cessation
- 1993-11-06 RU RU95112484/04A patent/RU2115650C1/ru not_active IP Right Cessation
-
1995
- 1995-05-08 FI FI952204A patent/FI952204A/fi unknown
- 1995-05-08 NO NO951797A patent/NO304467B1/no not_active IP Right Cessation
- 1995-05-30 BG BG99679A patent/BG62519B1/bg unknown
-
1998
- 1998-03-17 GR GR980400582T patent/GR3026386T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL308757A1 (en) | 1995-08-21 |
| NO951797D0 (no) | 1995-05-08 |
| CZ288595B6 (cs) | 2001-07-11 |
| BG99679A (bg) | 1996-04-30 |
| NO304467B1 (no) | 1998-12-21 |
| RU2115650C1 (ru) | 1998-07-20 |
| SK280522B6 (sk) | 2000-03-13 |
| BG62519B1 (bg) | 2000-01-31 |
| DK0667866T3 (da) | 1998-05-25 |
| FI952204A0 (fi) | 1995-05-08 |
| DE69317436D1 (de) | 1998-04-16 |
| ES2113081T3 (es) | 1998-04-16 |
| AU5464494A (en) | 1994-06-08 |
| CZ117695A3 (en) | 1996-06-12 |
| RU95112484A (ru) | 1997-04-20 |
| EP0667866A1 (en) | 1995-08-23 |
| DE69317436T2 (de) | 1998-07-02 |
| AU680639B2 (en) | 1997-08-07 |
| CA2148584A1 (en) | 1994-05-26 |
| FI952204A (fi) | 1995-05-08 |
| EP0667866B1 (en) | 1998-03-11 |
| WO1994011360A1 (en) | 1994-05-26 |
| KR100313649B1 (ko) | 2002-02-28 |
| NO951797L (no) | 1995-05-24 |
| ATE163927T1 (de) | 1998-03-15 |
| GR3026386T3 (en) | 1998-06-30 |
| PL179401B1 (pl) | 2000-08-31 |
| HU9501352D0 (en) | 1995-06-28 |
| US5580866A (en) | 1996-12-03 |
| NZ257843A (en) | 1996-10-28 |
| KR950704283A (ko) | 1995-11-17 |
| HUT71819A (en) | 1996-02-28 |
| UA41342C2 (uk) | 2001-09-17 |
| SK58895A3 (en) | 1995-09-13 |
| JPH08503202A (ja) | 1996-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI952204A (fi) | Terapeuttisia aineita | |
| NO961435L (no) | Terapeutiske midler | |
| ZA943241B (en) | Therapeutic agents | |
| PL312251A1 (en) | Isoquinoline derivatives as therapeutic agents | |
| IL107486A0 (en) | Therapeutic agents | |
| JO1728B1 (en) | Therapeutic agents | |
| JO1785B1 (en) | Therapeutic agents | |
| JO1809B1 (en) | Therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EG | Technical examination (opinion): publication of technical examination (opinion) | ||
| FC | Decision: refusal |